Empagliflozin in Patients with Chronic Kidney Disease - Herrington, William G; Staplin, Natalie; Wanner, Christoph; Green, Jennifer B; Hauske, Sibylle J; Emberson, Jonathan R; Preiss, David; Judge, Parminder; Mayne, Kaitlin J; Ng, Sarah Y A; Sammons, Emily; Zhu, Doreen; et al. (The New England journal of medicine, 2023)
Keywords: Albumin; Antidiabetics; Benzhydryl Compounds - adverse effects; Benzhydryl Compounds - therapeutic use; Cardiology; Cardiovascular Diseases - chemically induced; Chronic Kidney Disease; Clinical Medicine; Clinical Medicine General; Congestive heart failure; Creatinine; Creatinine - urine; Death; Design; Diabetes; Diabetes mellitus; Diabetes Mellitus, Type 2 - complications; Diabetes Mellitus, Type 2 - drug therapy; Disease Progression; End-stage renal disease; Endocrinology; Epidermal growth factor receptors; Glomerular Filtration Rate; Heart failure; Hemodialysis; Hospitalization; Humans; Kidney - physiopathology; Kidney diseases; Kidney transplants; Nephrology; Patient safety; Placebos; Prevention; Renal Insufficiency, Chronic - complications; Renal Insufficiency, Chronic - drug therapy; Sodium-Glucose Transporter 2 Inhibitors - adverse effects; Sodium-Glucose Transporter 2 Inhibitors - therapeutic use; Statistical analysis; Values